Stocks in play: HLS Therapeutics Inc.
Has entered into a Product Listing Agreement (PLA) with the province of British Columbia ("BC"), for the listing and public reimbursement of Vascepa (icosapent ethyl). The PLA with BC PharmaCare is effective February 6. HLS Therapeutics Inc. shares V.HLS are trading down $0.02 at $4.26.
Read:
Innovative Strategies in the Fight Against Pancreatic Cancer: A 2023 Recap
Lithium M&A Activity Heats Up Again on New Deals in Argentina’s Lithium Triangle
South America's Lithium Potential Sparks Global Competition Amid Renewable Energy Push
South America's Lithium Potential Sparks Global Competition Amid Renewable Energy Push